Acadia Pharmaceuticals sell The Goldman Sachs Group, Inc.
Start price
07.08.25
/
50%
€20.93
Target price
07.08.26
€14.58
Performance (%)
-13.81%
Price
16.04.26
€18.04
Summary
This prediction is currently active. The price of Acadia Pharmaceuticals has decreased since the start of the prediction. Compared to the start price this results in a performance of -13.81%. This prediction currently runs until 07.08.26. The prediction end date can be changed by The_Goldman_Sachs_Gr at any time. The_Goldman_Sachs_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Acadia Pharmaceuticals | -5.376% | -5.376% |
| iShares Core DAX® | 0,79 % | 1,97 % |
| iShares Nasdaq 100 | 4,23 % | 4,34 % |
| iShares Nikkei 225® | 3,29 % | 6,99 % |
| iShares S&P 500 | 2,50 % | 2,76 % |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Acadia Pharmaceuticals diskutieren
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $15.00 to $17.00. They now have a "sell" rating on the stock.
Ratings data for ACAD provided by MarketBeat